Oral gamma-secretase inhibitorImmunome

Varegacestat

Varegacestat (AL102) is an oral gamma-secretase inhibitor that suppresses Notch signaling. Immunome is developing it for progressing desmoid tumors, where it has shown high response rates.

Also known as: AL102

Forecast a trial in the Arena Browse all benchmarks

Trials tracked

Resolved

Indications

Targets

Varegacestat forecasting benchmarks

1 benchmark

ResolvedPhase 3

RINGSIDE Phase 3: varegacestat in desmoid tumors

Varegacestat · Desmoid tumors

Clinical Trials

Mechanism & molecular targets

γ-secretase· pathway

Indications studied

Desmoid tumors

Developed by

Immunome· IMNM

About Varegacestat

What is Varegacestat?

Varegacestat (AL102) is an oral gamma-secretase inhibitor that suppresses Notch signaling. Immunome is developing it for progressing desmoid tumors, where it has shown high response rates. It is a oral gamma-secretase inhibitor developed by Immunome.

What does Varegacestat target?

Varegacestat acts on Gamma-secretase (Notch pathway).

How well do AI models predict Varegacestat trial outcomes?

Open any benchmark below to see the full model leaderboard scored by accuracy, Brier score, and log loss. Models forecast each readout before it is public, so the scores reflect genuine predictive skill rather than hindsight.

References

Keep exploring

All benchmarks Diseases Companies Targets & genes